Long-term vitamin D and high-dose n-3 fatty acids' supplementation improve markers of cardiometabolic risk in type 2 diabetic patients with CHD.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

This study was performed to evaluate the effects of vitamin D and n-3 fatty acids' co-supplementation on markers of cardiometabolic risk in diabetic patients with CHD.

Why It Was Studied

This randomised, double-blinded, placebo-controlled trial was conducted among sixty-one vitamin D-deficient diabetic patients with CHD.

At baseline, the range of serum 25-hydroxyvitamin D levels in study participants was 6·3-19·9 ng/ml.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

At baseline, the range of serum 25-hydroxyvitamin D levels in study participants was 6·3-19·9 ng/ml.

Topics PubMed links to this paper include Biomarkers, Blood Glucose, Coronary Disease, Diabetes Mellitus, Type 2, Dietary Supplements, Fatty Acids, Omega-3 and Insulin.

Author keywords: Cardiometabolic risk, Coronary heart disease, Type 2 diabetes mellitus, Vitamin D supplementation and n-3 Fatty acids.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The publication is from 2019 (The British journal of nutrition), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.